Vernalis plc (LON:VER)‘s stock had its “hold” rating restated by analysts at Panmure Gordon in a research note issued on Monday. They presently have a GBX 31 ($0.40) target price on the stock. Panmure Gordon’s price target indicates a potential upside of 87.88% from the company’s current price.

Several other equities analysts have also weighed in on VER. Numis Securities Ltd reissued an “add” rating and issued a GBX 29 ($0.38) target price on shares of Vernalis plc in a research note on Friday, April 21st. Stifel Nicolaus cut their target price on Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.31) and set a “hold” rating on the stock in a research note on Friday, April 21st. N+1 Singer reissued a “hold” rating and issued a GBX 28 ($0.36) target price on shares of Vernalis plc in a research note on Friday, April 21st. Finally, RX Securities reissued a “buy” rating on shares of Vernalis plc in a research note on Monday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of GBX 39.40 ($0.51).

Shares of Vernalis plc (VER) opened at 16.00 on Monday. Vernalis plc has a 12 month low of GBX 15.98 and a 12 month high of GBX 46.00. The firm has a 50-day moving average of GBX 18.10 and a 200 day moving average of GBX 22.27. The company’s market capitalization is GBX 84.22 million.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/vernalis-plcs-lonver-hold-rating-reaffirmed-at-panmure-gordon.html.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.